Understanding disease and treatment in older adults with liver cancer
Characterizing Disease Biology, Treatment Patterns and Toxicity in Older Adults With Advanced Hepatocellular Carcinoma
This study is trying to understand how liver cancer affects older adults and what treatments work best for them to help improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 84 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The University of Texas Health Science Center at San Antonio Academic / other |
| Locations | 1 site (San Antonio, Texas) |
| Trial ID | NCT03894917 on ClinicalTrials.gov |
What this trial studies
This observational study aims to recruit 84 older adults, aged 65 and above, who have been newly diagnosed with unresectable advanced hepatocellular carcinoma (HCC) at the UT Health Cancer Center in San Antonio. It utilizes comprehensive geriatric assessment tools to evaluate the unique disease characteristics and treatment patterns in this population. The study will collect data on treatment toxicities and markers of aging to identify barriers to treatment and risk factors for increased morbidity. The findings will inform the development of personalized treatment algorithms for older adults with HCC.
Who should consider this trial
Good fit: Ideal candidates for this study are older adults aged 65 and above with newly diagnosed, unresectable advanced hepatocellular carcinoma.
Not a fit: Patients with resectable hepatocellular carcinoma or those who have received prior systemic or locoregional therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment plans for older adults with hepatocellular carcinoma.
How similar studies have performed: While there have been studies focusing on geriatric assessments in cancer treatment, this specific approach to hepatocellular carcinoma in older adults is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologically or radiographically (CT or MRI) confirmed newly diagnosed hepatocellular carcinoma. * Age 18 years and older. * Patients with advanced, unresectable HCC as determined by the treating physician. Exclusion Criteria: * Patients with resectable HCC who are still candidates for locoregional therapy * Patients receiving prior systemic or locoregional therapy
Where this trial is running
San Antonio, Texas
- Mays Cancer Center — San Antonio, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Sukeshi Patel Arora, MD — Mays Cancer Center
- Study coordinator: Maggie Tomasini, MPH
- Email: tomasinim@uthscsa.edu
- Phone: 210-450-0507
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.